Financial reports
10-Q
2023 Q2
Quarterly report
4 Aug 23
10-Q
2023 Q3
Quarterly report
5 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
14 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
29 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
Current reports
8-K
Pardes Biosciences Announces Closing of Tender Offer
31 Aug 23
8-K
Entry into a Material Definitive Agreement
17 Jul 23
8-K
Departure of Directors or Certain Officers
5 Jun 23
8-K
Departure of Directors or Certain Officers
18 May 23
8-K
Pardes Biosciences Reports First Quarter 2023 Financial Results
5 May 23
8-K
Departure of Directors or Certain Officers
21 Apr 23
8-K
Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
3 Apr 23
8-K
Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
14 Mar 23
8-K
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
7 Nov 22
8-K
Departure of Directors or Certain Officers
17 Oct 22
Registration and prospectus
15-12G
Securities registration termination
11 Sep 23
25-NSE
Exchange delisting
31 Aug 23
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Aug 23
POS AM
Prospectus update (post-effective amendment)
31 Aug 23
POS AM
Prospectus update (post-effective amendment)
31 Aug 23
SC 13E3/A
Going private transaction (amended)
31 Aug 23
SC TO-T/A
Third party tender offer statement (amended)
31 Aug 23
SC 13E3/A
Going private transaction (amended)
31 Aug 23
SC 14D9/A
Tender offer solicitation (amended)
31 Aug 23
SC 13E3/A
Going private transaction (amended)
28 Aug 23
Other
CT ORDER
Confidential treatment order
18 Sep 23
EFFECT
Notice of effectiveness
1 Sep 23
EFFECT
Notice of effectiveness
1 Sep 23
CORRESP
Correspondence with SEC
28 Aug 23
UPLOAD
Letter from SEC
24 Aug 23
UPLOAD
Letter from SEC
24 Aug 23
CORRESP
Correspondence with SEC
17 Aug 23
UPLOAD
Letter from SEC
8 Aug 23
UPLOAD
Letter from SEC
8 Aug 23
EFFECT
Notice of effectiveness
23 Jan 23
Ownership
4
James B. Tananbaum
31 Aug 23
SC 13D/A
FS Development Holdings II, LLC
31 Aug 23
4
THOMAS G WIGGANS
31 Aug 23
4
Michael David Varney
31 Aug 23
4
Alsup Laurie Smaldone
31 Aug 23
4
John C Pottage Jr
31 Aug 23
4
Uri A Lopatin
31 Aug 23
4
J JAY LOBELL
31 Aug 23
4
Elizabeth H. Lacy
31 Aug 23
4
HEIDI HENSON
31 Aug 23